Table 1.

MRC results for nusinersen treated and untreated cohorts

Source	SMA TYPE	MRC baseline (mean + SD or mean (range))	Time from infusion/FU timing	N	MRC change
Nusinersen-treated cohorts
De Wel	3 and 4	36.9 + 10.3	14 months	15	Mean: 2.53, 99% CI 0.18–4.88
Walter	3	113.95 + 22.91	10 months	16	Mean: 4.55
Mosche-Lilie	2 and 3	Not reported	12 months	10	Mean %: + 2.13%
Untreated cohorts
Wjngaarde	2A	Not reported	12 months	68	Annual slope: − 0.73, 95% CI − 1.00; − 0.45
Wjngaarde	2B	Not reported	12 months	50	Annual slope: − 0.65, 95% CI − 0.89; − 0.40
Wjngaarde	3A	Not reported	12 months	63	Annual slope: − 0.84, 95% CI − 1.07; − 0.61
Wjngaarde	3B	Not reported	12 months	40	Annual slope: − 0.83, 95% CI − 1.13; − 0.54
Carter GT	2	Mean 2.3 + 0.6*	10 years	18	Decade slope − 0.24 per muscle
Piepers 2008	3B and 4	Mean 294 + 12	Mean 30 months (19–36 months)	9	Mean change: 0
Wadman	1C, 2, 3, 4	Not reported	12 months	180	Annual slope: − 1
Werlauff	2	29% (9–41)	Median 17 years (12–20 years)	21	Annual slope: − 0.22 (Upper limb), CI − 0.39; − 0.02
Otto 2020	2 and 3	142.7 + 41.6	Mean 13.1 months (368–442 days)	9	Mean change: − 1.1

Key to table: *average grade for all muscles groups combined